Sunday, October 24, 2021

Kenya receives 200,000 Sinopharm COVID-19 vaccines


Kenya through the Ministry of Health has received 200,000 doses of the Sinopharm COVID-19 vaccine from the government of China.

“This morning it’s a special moment as Kenya receives, for the first time, some 200,000 Sinopharm Covid-19 Vaccine doses from China.” Said Ministry of Health.

- Advertisement -

Speaking during the handing over ceremony, PS Susan Mochache noted that the consignment was a demonstration of the good relationship between the two countries.

“The vaccines we are receiving today are testament to the cordial relations that exist between our two countries that extend beyond health care to include trade and other sectors of development.

I would like to take this opportunity to thank the people of China represented here by the Minister Counselor to Kenya for this support to our vaccination exercise.” Said PS Mochache.

The country now has five types of vaccines which include AstraZeneca, Moderna, Johnson and Johnson, Pfizer, and now Sinopharm.

Like Oxford/Astrazeneca, the Sinopharm vaccine is a two-dose vaccine with the recipient required to be administered 28 days apart. Its storage is between 2 and 8 degrees.

“The Sinopharm vaccine is a two-dose vaccine with a 28-day gap between the first and second dose. In addition, the storage condition is 2 to 8 degrees. This will therefore fit in very well in the current cold chain storage capacity we have in our vaccine stores.

Although this consignment has been delivered courtesy of our strong bilateral relations, Sinopharm is also available through the Government of Kenya engagement with the COVAX mechanism & we shall be getting more supplies through that platform in the near future.

We are once again appealing to our people who have not been vaccinated to use this chance to do so in order to protect yourself and your loved ones. Like we have stated before all vaccines are the same and perform the same function.” Said Ministry of Health

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected

- Advertisement -

Latest Articles